Iberdomide (CC-220) Monotherapy or in Combination with an Anti-CD20 Monoclonal Antibody As Effective Therapy in Patients with Relapsed/Refractory Lymphoma: Early Results from a Phase 1/2 Study
Catherine Thiéblemont(Université Paris Cité), Franck Morschhauser(Hôpital Claude Huriez), Luca Arcaini(University of Pavia), Mark H. Kaplan(Indiana University – Purdue University Indianapolis), James Drew(Bristol-Myers Squibb (United States)), Guillaume Cartron(Hôpital Saint Eloi), Peter Martin(Northwestern University), Vladan Vučinić(University Hospital Leipzig), Carlo Visco(University of Verona), Argyrios Gkasiamis(Bristol-Myers Squibb (Switzerland)), Paolo Corradini(Gruppo di Ricerca Geriatrica), Grzegorz S. Nowakowski(Université Claude Bernard Lyon 1), Thomas Gastinne(Nantes Université), Alessandra Tucci(Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia), Shekeab Jauhari(Merus (Netherlands)), Louise Roulin(Assistance Publique – Hôpitaux de Paris), Javier Muñoz(The University of Texas MD Anderson Cancer Center), Max S. Topp(Universitätsklinikum Würzburg), L. Ju(The University of Western Australia), Yiming Cheng(Bristol-Myers Squibb (Germany)), Ian W. Flinn(Tennessee Oncology), Kamal Bouabdallah(Université de Bordeaux), Parth Rao(Bristol-Myers Squibb (United States))
Cited by 16
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Frequent Detection and Isolation of Cytopathic Retroviruses (HTLV-III) from Patients with AIDS and at Risk for AIDS
|Science|1984|3.6k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2020|1.9k